{
  "nctId": "NCT03762330",
  "briefTitle": "Structured Comprehensive Intervention to Stimulate Self- Management and Improve Quality of Life in COPD Patients",
  "officialTitle": "Effect of a Structured Comprehensive Intervention to Stimulate Self- Management and Improve Quality of Life in People With Chronic Obstructive Pulmonary Disease(COPD). A Randomised Clinical Trial.",
  "protocolDocument": {
    "nctId": "NCT03762330",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2017-03-29",
    "uploadDate": "2018-11-26T02:33",
    "size": 210431,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03762330/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 300,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2019-01-19",
    "completionDate": "2021-01",
    "primaryCompletionDate": "2021-01",
    "firstSubmitDate": "2018-11-14",
    "firstPostDate": "2018-12-03"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Patients with at least one visit at the primary care physician during the past year\n* Patients with a diagnosis of moderate (FEV1 50% - 80%) or severe (FEV1 30% - 50%) COPD\n* Patients treated with inhaled bronchodilators and accepting to participate in the study.\n\nExclusion Criteria:\n\n* Patients unable to come to the primary care centre\n* Patients with cognitive impairment and/or a severe mental condition.\n* Patients with a diagnosis of asthma, tuberculosis or other chronic respiratory disease.\n* Patients needing chronic oxygen therapy.\n* Patients with any terminal disease",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Quality of life St. George´s Respiratory Questionnaire (SGRQ)",
        "description": "St. George´s Respiratory Questionnaire (SGRQ).Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease.\n\nNumber of items: 50 items Number of domains \\& categories : 2 parts (3 components). Part 1 : Symptoms component (frequency \\& severity) with a 1, 3 or 12-month recall (best performance with 3- and 12-month recall); Part 2: Activities that cause or are limited by breathlessness; Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall.\n\nScaling of items Part I (Symptoms): several scales; Part II (Activity and Impacts): dichotomous (true/false) except last question (4-point Likert scale). Scores range from 0 to 100, with higher scores indicating more limitations.",
        "timeFrame": "Change from baseline at 6 ,12 and 24 months"
      }
    ],
    "secondary": [
      {
        "measure": "Intensity of symptoms related to COPD",
        "description": "COPD Assessment Test (CAT) : It consists of 8 questions with 5 possible answers valued from 0 to 5 (values close to 0: better health status)",
        "timeFrame": "Change from baseline at 6 ,12 and 24 months"
      },
      {
        "measure": "Dyspnea score severity",
        "description": "Dyspnea severity assessed by the modified scale of the Medical Research Council (mMRC). Range 0-4 (none to maximum)",
        "timeFrame": "Change from baseline at 6 ,12 and 24 months"
      },
      {
        "measure": "Changes in the Body mass index, Obstruction, Dyspnea, Exacerbations Index (BODEx index )",
        "description": "Index including BMI (Body mass index), Obstruction, Dyspnea, Exacerbations. with possible answers from 0-3, each item. Range: 0-9. Mild: 0-2 Moderate: 3-4 Severe ≥5",
        "timeFrame": "Change from baseline at 6 ,12 and 24 months"
      },
      {
        "measure": "Number of COPD exacerbations",
        "description": "Number of COPD exacerbations requiring a visit to primary care physician",
        "timeFrame": "at 6 ,12 and 24 months from baseline"
      },
      {
        "measure": "Number of hospital admissions due to COPD exacerbation",
        "description": "Number of hospital admissions due to COPD exacerbation",
        "timeFrame": "at 6 ,12 and 24 months from baseline"
      },
      {
        "measure": "Changes in Anxiety and depression scales",
        "description": "Goldberg's anxiety-depression scale (GADS): is an 18-item self-report symptom inventory that was developed by Goldberg and colleagues from 36 items in the Psychiatric Assessment Schedule. The GADS score is based on responses of 'yes' or 'no' to nine depression and nine anxiety items, asking how respondents have been feeling in the past month. Goldberg et al. (1988) considered patients with anxiety scores of 5 or more or with depression scores of 2 or more as having a 50% chance of a clinically important disturbance",
        "timeFrame": "Change from baseline at 6 ,12 and 24 months"
      },
      {
        "measure": "Changes in forced vital capacity (FVC)",
        "description": "Value of FVC measured with forced spirometry",
        "timeFrame": "Change from baseline at 6 ,12 and 24 months"
      },
      {
        "measure": "Changes in forced expiratory volume at the first second (FEV1)",
        "description": "Value of FEV1 measured with forced spirometry",
        "timeFrame": "Change from baseline at 6 ,12 and 24 months"
      },
      {
        "measure": "Results of the Test of Adherence to Inhalers (TAI test)",
        "description": "TAI test. Includes 10 questions self-completed by patient. Range of each questions; 1worse compliance and 5 best compliance. The total score of the 10 items gives a total from 1-50.",
        "timeFrame": "Change from baseline at 6 ,12 and 24 months"
      },
      {
        "measure": "Use of long-acting beta-adrenergic bronchodilator in monotherapy",
        "description": "Use of long-acting beta-adrenergic bronchodilator in monotherapy (yes or no)",
        "timeFrame": "At baseline and at 6 ,12 and 24 months"
      },
      {
        "measure": "Use of long-acting anticholinergic bronchodilator in monotherapy",
        "description": "Use of long-acting anticholinergic bronchodilator in monotherapy (yes or no)",
        "timeFrame": "At baseline and at 6 ,12 and 24 months"
      },
      {
        "measure": "Use of a double therapy of long-acting beta-adrenergic bronchodilator and long-acting anticholinergic bronchodilator",
        "description": "Use of a double therapy of long-acting beta-adrenergic bronchodilator and long-acting anticholinergic bronchodilator (yes or no)",
        "timeFrame": "At baseline and at 6 ,12 and 24 months"
      },
      {
        "measure": "Use of a double therapy of long-acting beta-adrenergic bronchodilator and short-acting anticholinergic bronchodilator",
        "description": "Use of a double therapy of long-acting beta-adrenergic bronchodilator and short-acting anticholinergic bronchodilator (yes or no)",
        "timeFrame": "At baseline and at 6 ,12 and 24 months"
      },
      {
        "measure": "Use of a triple therapy of long-acting beta-adrenergic bronchodilator and long-acting anticholinergic bronchodilator plus inhaled steroids",
        "description": "Use of a triple therapy of long-acting beta-adrenergic bronchodilator plus long-acting anticholinergic bronchodilator plus inhaled steroids (yes or no)",
        "timeFrame": "At baseline and at 6 ,12 and 24 months"
      },
      {
        "measure": "Use of a triple therapy of long-acting beta-adrenergic bronchodilator and short-acting anticholinergic bronchodilator plus inhaled steroids",
        "description": "Use of a triple therapy of long-acting beta-adrenergic bronchodilator and short-acting anticholinergic bronchodilator plus inhaled steroids (yes or no)",
        "timeFrame": "At baseline and at 6 ,12 and 24 months"
      },
      {
        "measure": "Use of Roflumilast",
        "description": "Use of Roflumilast (yes or no)",
        "timeFrame": "At baseline and at 6 ,12 and 24 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 16,
      "otherCount": 0,
      "totalCount": 17
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:27.033Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}